Prostate cancer: Blood test could predict how well patients will respond to treatment, research suggests

Liquid biopsy could also help identify people more likely to relapse, scientists say

Zoe Tidman
Sunday 31 May 2020 08:26
Comments
Test can help doctors ‘stay one step ahead of the disease’
Test can help doctors ‘stay one step ahead of the disease’

A simple blood test could be used to predict how well men with prostate cancer will respond to treatment, according to new research.

This liquid biopsy could also help identify the patients who are more likely to relapse, scientists have said.

The non-invasive test – which is less painful than tissue biopsies – could lead to tailored treatment for those in the advanced stages of the prostate cancer, according to The Institute of Cancer Research, London (ICR).

It could also allow doctors to stop drugs for certain patients that are unlikely to work as soon as possible, they added.

A team of researchers from ICR and The Royal Marsden NHS Foundation Trust analysed over 1,000 blood samples from patients with prostate cancer.

They said the tests can detect traces of cancer in the bloodstream and could help track how the disease evolves and responds to treatment.

Professor Paul Workman, ICR’s chief executive, said the “simple blood tests” can ”help us anticipate cancer’s next move”.

He added: “They can help doctors come up with personalised treatment plans and to stay one step ahead of the disease.”

The study focused on men who were part of a clinical trial looking at the benefit of abiraterone, a targeted drug, with or without an experimental drug, ipatasertib.

The results showed that men with high levels of tumour DNA at the start of treatment had a significantly worse outcome.

After monitoring patients with repeat blood tests, the team of researchers also found those who responded to treatment had the greatest fall in the amount of cancer DNA in their bloodstream.

Scientists also found through analysis of DNA from the blood tests that there were specific genetic changes associated with drug resistance, indicating risk of early relapse.

“Our study shows that a simple blood test could help us track how cancer evolves and responds to treatment – initially as part of clinical trials and eventually in routine care,” Professor Johann de Bono, professor of experimental cancer medicine at the ICR, said.

“These so-called liquid biopsy tests are minimally invasive, cost-effective and can be performed often and with ease.”

The consultant medical oncologist at The Royal Marsden trust added: “Tracking prostate cancer with a blood test instead of a painful surgical biopsy could significantly improve patients’ quality of life.

“Our study offers further evidence for the huge potential of liquid biopsies to help guide treatment, design personal treatment plans and improve patient outcomes.”

Prostate cancer is the most common cancer in men in the UK, with more than 47,500 men diagnosed every year, according to Prostate Cancer UK.

Additional reporting by Press Association

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in